Cargando…
Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia
AIMS/HYPOTHESIS: Heterozygous glucokinase (GCK) mutations cause mild, fasting hyperglycaemia from birth. Although patients are usually asymptomatic and have glycaemia within target ranges, some are put on pharmacological treatment. We aimed to investigate how many patients are on pharmacological tre...
Autores principales: | Stride, Amanda, Shields, Beverley, Gill-Carey, Olivia, Chakera, Ali J., Colclough, Kevin, Ellard, Sian, Hattersley, Andrew T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855531/ https://www.ncbi.nlm.nih.gov/pubmed/24092492 http://dx.doi.org/10.1007/s00125-013-3075-x |
Ejemplares similares
-
Use of HbA1c in the Identification of Patients with Hyperglycaemia Caused by a Glucokinase Mutation: Observational Case Control Studies
por: Steele, Anna M., et al.
Publicado: (2013) -
Antenatal Diagnosis of Fetal Genotype Determines if Maternal Hyperglycemia Due to a Glucokinase Mutation Requires Treatment
por: Chakera, Ali J., et al.
Publicado: (2012) -
Response to Comment on: Chakera et al. Antenatal Diagnosis of Fetal Genotype Determines if Maternal Hyperglycemia due to a Glucokinase Mutation Requires Treatment. Diabetes Care 2012;35:1832–1834
por: Chakera, Ali J., et al.
Publicado: (2013) -
South Asian individuals with diabetes who are referred for MODY testing in the UK have a lower mutation pick-up rate than white European people
por: Misra, Shivani, et al.
Publicado: (2016) -
Syndromic monogenic diabetes genes should be tested in patients with a clinical suspicion of MODY
por: Colclough, Kevin, et al.
Publicado: (2022)